Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 53,994,024
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 47,291 M
  • Annual Income, $ -11,988 M
  • 60-Month Beta 1.27
  • Price/Sales 1.13
  • Price/Cash Flow 2.49
  • Price/Book 1.51
Trade BAYRY with:
  • Price/Earnings ttm 7.21
  • Earnings Per Share ttm 1.89
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/02/21
  • Annual Dividend & Yield 0.41 (2.96%)
  • Most Recent Dividend 0.415 on 04/28/21
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.31
  • Number of Estimates 1
  • High Estimate 0.31
  • Low Estimate 0.31
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.1000 +4.66%
on 09/20/21
14.3000 -4.13%
on 09/02/21
-0.3895 (-2.76%)
since 08/24/21
3-Month
13.1000 +4.66%
on 09/20/21
15.5400 -11.78%
on 07/02/21
-1.6400 (-10.68%)
since 06/24/21
52-Week
11.6500 +17.68%
on 10/30/20
17.3400 -20.93%
on 05/14/21
-2.1800 (-13.72%)
since 09/24/20

Most Recent Stories

More News
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

REGN : 638.90 (-1.18%)
MRK : 73.61 (+0.77%)
BAYRY : 13.7100 (-0.22%)
BLU : 6.37 (+0.79%)
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer

Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.

RHHBY : 46.0100 (-0.88%)
BMY : 60.23 (-0.66%)
BAYRY : 13.7100 (-0.22%)
EXEL : 20.35 (-0.73%)
Global Immunotherapy Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview 2029

Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.

MRK : 73.61 (+0.77%)
GILD : 71.19 (-0.70%)
PFE : 43.94 (-0.57%)
AZN : 60.35 (+1.46%)
BMY : 60.23 (-0.66%)
GSK : 38.39 (-2.41%)
RHHBY : 46.0100 (-0.88%)
NVS : 82.93 (-0.77%)
BAYRY : 13.7100 (-0.22%)
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

REGN : 638.90 (-1.18%)
BAYRY : 13.7100 (-0.22%)
ABBV : 107.07 (-0.27%)
RGNX : 42.32 (-2.67%)
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.

SNY : 47.94 (-1.60%)
AZN : 60.35 (+1.46%)
PFE : 43.94 (-0.57%)
MRK : 73.61 (+0.77%)
LLY : 231.68 (-0.22%)
BAYRY : 13.7100 (-0.22%)
Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal

Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.

REGN : 638.90 (-1.18%)
IRWD : 13.45 (+3.54%)
VRTX : 183.61 (-0.80%)
BAYRY : 13.7100 (-0.22%)
Topical Drug Delivery Market Report 2021: The Market is Shifting Toward Quality, Safety, and Efficacious Products – Forecast to 2028

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include GlaxoSmithKline...

BAYRY : 13.7100 (-0.22%)
CRRTF : 0.5416 (-2.34%)
NVS : 82.93 (-0.77%)
VRX.TO : 30.80 (-3.33%)
Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data

FDA approves Pfizer's (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.

AZN : 60.35 (+1.46%)
NVS : 82.93 (-0.77%)
JNJ : 164.36 (-0.30%)
PFE : 43.94 (-0.57%)
MRK : 73.61 (+0.77%)
BAYRY : 13.7100 (-0.22%)
ABBV : 107.07 (-0.27%)
Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal

Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.

REGN : 638.90 (-1.18%)
NVS : 82.93 (-0.77%)
BAYRY : 13.7100 (-0.22%)
HZNP : 110.37 (+0.80%)
Blood Cancer Drugs Global Market Report 2021: Leukemia, Lymphoma, Myeloma - Forecast to 2030 - ResearchAndMarkets.com

The "Blood Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

AMGN : 213.61 (-0.67%)
AZN : 60.35 (+1.46%)
BAYRY : 13.7100 (-0.22%)
CELGZ : 0.47 (+2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 13.8300
2nd Resistance Point 13.7700
1st Resistance Point 13.7400
Last Price 13.7100
1st Support Level 13.6500
2nd Support Level 13.5900
3rd Support Level 13.5600

See More

52-Week High 17.3400
Fibonacci 61.8% 15.1664
Fibonacci 50% 14.4950
Fibonacci 38.2% 13.8236
Last Price 13.7100
52-Week Low 11.6500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar